Tumor radiosensitivity (SF2) is a prognostic factor for local control in head and neck cancers

International Journal of Radiation Oncology Biology Physics

Volumn 46, Issue 1, 2000, Pages 13-19

  Björk Eriksson, Thomas ^a   West, Catharine ^b   Karlsson, Ewa ^a   Mercke, Claes ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Head and neck cancers; Predictive assays; Radiosensitivity; SF2

Indexed keywords

CISPLATIN; FLUOROURACIL; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CLONOGENIC ASSAY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RADIOSENSITIVITY; ADJUVANT THERAPY; CARCINOMA; COMPARATIVE STUDY; HEAD AND NECK TUMOR; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; RADIATION DOSE; RADIATION RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PROGNOSIS; PROSPECTIVE STUDIES; RADIATION TOLERANCE;

EID: 0033621687     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(99)00373-9     Document Type: Article

References (24)

1. Lee W.R., Mendenhall W.M., Parsons J.T., et al. Carcinoma of the tonsillar region A multivariate analysis of 243 patients treated with radical radiotherapy . Head Neck. 15:1993;283-288.
2. Induction chemotherapy plus radiotherapy compared with surgery plus radiotherapy in patients with advanced laryngeal cancer. N Engl J Med. 324:1991;1685-1690.
3. Spaulding M., Fischer S., Wolf G., et al. Tumor response, toxicity, and survival after neoadjuvant organ-preserving chemotherapy for advanced laryngeal carcinoma. J Clin Oncol. 12:1994;1592-1599.
4. Harrison L., Lee H., Pfister D., et al. Long term results of primary radiotherapy with/without neck dissection for squamous cell cancer of the base of tongue. Head Neck. 20:1998;668-673.
5. Harrison L., Zelefsky M., Pfister M., et al. Detailed quality of life assessment in patients treated with primary radiotherapy for squamous cell cancer of the base of the tongue. Head Neck. 19:1997;169-175.
6. Deacon J., Peckham M.J., Steel G.G. The radioresponsiveness of human tumours and the initial slope of the cell survival curve. Radiother Oncol. 2:1984;317-323.
7. Fertil B., Malaise E.-P. Inherent cellular radiosensitivity as a basic concept for human tumor radiotherapy. Int J Radiat Oncol Biol Phys. 7:1981;621-629.
8. Bristow R.G., Hill R.P. Comparison between in vitro radiosensitivity and in vivo radioresponse in murine tumor cell lines II In vivo radioresponse following fractionated treatment and in vitro/in vivo correlations . Int J Radiat Oncol Biol Phys. 18:1990;331-345.
9. Tucker S.L., Thames H.D. The effect of patient-to patient variability on the accuracy of predictive assays of tumor response to radiotherapy-a theoretical evaluation. Int J Radiat Oncol Biol Phys. 17:1989;145-157.
10. West C.M.L., Davidson S.E., Roberts S.A., et al. Intrinsic radiosensitivity and prediction of patient response to radiotherapy for carcinoma of the cervix. Br J Cancer. 68:1993;819-823.
11. West C.M.L., Davidson S.E., Roberts S.A., et al. The independence of intrinsic radiosensitivity as a prognostic factor for patient response to radiotherapy of carcinoma of the cervix. Br J Cancer. 76:1997;1184-1190.
12. Brock W.A., Brown B.W., Goefpert H., et al. In vitro radiosensitivity of tumor cells and local control by radiotherapy. Dewey W.C., Edington M., Fry R.J.M., Hall E.J., Whitmore G.F. Radiation research A Twentieth Century perspective . 1992;696-699 Academic Press, San Diego.
13. Girinsky T., Lubin R., Pignon J., et al. Predictive value of in vitro radiosensitivity parameters in head and neck cancers and cervical carcinomas Preliminary correlations with local control and overall survival . Int J Radiat Oncol Biol Phys. 25:1993;3-7.
14. Eschwege F., Bourhis J., Girinsky T., et al. Predictive assays of radiation response in patients with head and neck squamous cell carcinoma A review of the Institute Gustave Roussy experience . Int J Radiat Oncol Biol Phys. 39:1997;849-853.
15. Stausböl-Grön B., Overgaard J. Relationship between tumour cell in vitro radiosensitivity and clinical outcome after curative radiotherapy for squamous cell carcinoma of the head and neck. Radiother Oncol. 50:1999;47-55.
16. Spiessl B, Beahrs OH, Hermanet P; et al. International union against cancer TNM atlas illustrated guide to the TNM/pTNM classification of malignant tumours. Berlin: Springer Verlag; 1989. pp. 4-9.
17. Report 50 Prescribing, recording and reporting photon beam therapy . 1993;International Commission on Radiation Units and Measurements, Bethesda, MD.
18. Report 58 Dose and volume specification for reporting interstitial therapy . 1997;International Commission on Radiation Units and Measurements, Bethesda, MD.
19. Björk-Eriksson T., West C.M.L., Karlsson E., et al. The in vitro radiosensitivity of human head and cancers. Br J Cancer. 77:1998;2371-2375.
20. Davidson S.E., West C.M.L., Roberts S.A. Radiosensitivity testing of primary cervical carcinoma Evaluation of intra- and inter-tumour heterogeneity . Radiother Oncol. 18:1990;349-356.
21. Björk-Eriksson T., West C.M.L., Karlsson E., et al. Discrimination of human tumor radioresponsiveness using low-dose rate irradiation. Int J Radiat Oncol Biol Phys. 42:1998;1147-1153.
22. Corvò R., Sanguineti G., Scala M., et al. Primary site as predictive factor of local control in advanced head and neck tumors treated by concomitant boost accelerated radiotherapy. Tumori. 80:1994;135-138.
23. Lawton P., Hodgkiss R., Eyden B., et al. Growth of fibroblasts as a potential confounding factor in soft agar clonogenic assays for tumour cell radiosensitivity. Radiother Oncol. 32:1994;218-225.
24. Björk-Eriksson T., West C.M.L., Cvetskovska E., et al. The lack of correlation between proliferation (Ki-67, PCNA, LI, Tpot), p53 expression and radiosensitivity for head and neck cancers. Br J Cancer. 80:1999;1400-1404.